9.20

0.66% 0.06

Theravance Biopharma Inc (TBPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$9.14

Offen:

$9.13

24-Stunden-Volumen:

288.74K

Relative Volume:

1.11

Marktkapitalisierung:

$460.00M

Einnahmen:

$62.02M

Nettoeinkommen (Verlust:

$-45.65M

KGV:

-10.00

EPS:

-0.92

Netto-Cashflow:

$-9.60M

1W Leistung:

+2.45%

1M Leistung:

+7.04%

6M Leistung:

-3.36%

1J Leistung:

-4.17%

1-Tages-Spanne:

$9.04

$9.37

1-Wochen-Bereich:

$8.33

$9.37

52-Wochen-Spanne:

$7.44

$10.90

Theravance Biopharma Inc Stock (TBPH) Company Profile

Firmenname

Theravance Biopharma Inc

Sektor

Healthcare (1170)

Branche

Biotechnology (671)

Telefon

650-808-6000

Adresse

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

TBPH's Discussions on Twitter

Vergleichen Sie TBPH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TBPH Theravance Biopharma Inc	9.20	449.01M	62.02M	-45.65M	-9.60M	-0.92
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-06	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-04-12	Eingeleitet	BTIG Research	Buy
2024-01-08	Herabstufung	Evercore ISI	Outperform → In-line
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2021-11-05	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-15	Herabstufung	JP Morgan	Overweight → Underweight
2021-08-25	Herabstufung	Morgan Stanley	Overweight → Underweight
2021-08-24	Herabstufung	Cowen	Outperform → Market Perform
2020-10-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Eingeleitet	JP Morgan	Overweight
2020-06-15	Eingeleitet	Morgan Stanley	Equal-Weight
2020-05-13	Eingeleitet	Cowen	Outperform
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-06	Hochstufung	Robert W. Baird	Underperform → Neutral
2019-10-29	Eingeleitet	H.C. Wainwright	Buy
2018-03-29	Fortgesetzt	Piper Jaffray	Overweight
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-06-16	Eingeleitet	Cantor Fitzgerald	Overweight
2017-05-11	Bestätigt	Needham	Buy
2016-12-21	Eingeleitet	Needham	Buy
2016-11-03	Eingeleitet	Piper Jaffray	Overweight
2016-10-12	Herabstufung	Robert W. Baird	Neutral → Underperform
2016-08-03	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-06-20	Eingeleitet	Guggenheim	Buy
2016-06-20	Bestätigt	Leerink Partners	Outperform
2016-05-12	Eingeleitet	Leerink Partners	Outperform
2016-05-05	Herabstufung	BofA/Merrill	Buy → Neutral
2015-02-03	Hochstufung	Robert W. Baird	Underperform → Neutral

Alle ansehen

Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten

May 16, 2025

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by StockNews.com - Defense World

May 16, 2025

May 15, 2025

When (TBPH) Moves Investors should Listen - news.stocktradersdaily.com

May 15, 2025

May 13, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conf - GuruFocus

May 13, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune

May 13, 2025

Price T Rowe Associates Inc. MD Buys 9,315 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 13, 2025

Dimensional Fund Advisors LP Acquires 95,304 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 13, 2025

May 12, 2025

We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation - simplywall.st

May 12, 2025

May 10, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at th - GuruFocus

May 09, 2025

Theravance Biopharma, Inc. Announces Ampreloxetine Presentations At the International MSA Congress - marketscreener.com

May 09, 2025

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - Yahoo Finance

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News - GuruFocus

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - PR Newswire

May 09, 2025

Theravance Biopharma: Promising Future with Strong Product Pipeline and Market Expansion - TipRanks

May 09, 2025